Edward Z. Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edward Z. Song has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Jessica B. Foster
Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, USA
3 shared publications - Nicholas A. Vitanza
Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute, Seattle, USA
3 shared publications Andrea Timpanaro
Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute, Seattle, USA
2 shared publications- Lucy Z. Li
Center for Fundamental Immunology, Benaroya Research Institute, Seattle, USA
2 shared publications - Matthew C. Biery
Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute, Seattle, USA
2 shared publications - Matthew D. Dun
University of Newcastle
2 shared publications
Latest Publications
- Open Access
- 14 November 2025
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 1 (3)
Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor
- 14 November 2025
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 1 (3)
Open AccessViral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor
- Open Access
- 11 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma
Diffuse intrinsic pontine glioma (DIPG) is a fatal brainstem tumor desperately in need of better treatments. Chimeric antigen receptor (CAR) T cell therapies for DIPG have demonstrated clinical tolerability and bioactivity, but not universal benefit. A major obstacle is insufficient CAR T cell trafficking to the tumor. As our recent clinical trials have demonstrated locoregional elevation of CXCL10, a ligand of the chemokine receptor CXCR3, here we aim to leverage this CXCL10 upregulation to enhance cell trafficking by engineering our B7-H3-targeting CAR T cells to overexpress CXCR3 variants. We demonstrate that, compared to unmodified B7-H3 CAR T cells, CXCR3-A-modified CAR T cells migrate more efficiently toward CXCR3 ligands in vitro, and when delivered intracerebroventricularly in orthotopic DIPG mouse models, CXCR3-A-modified CAR T cells show enhanced trafficking into the tumor and improved therapeutic efficacy. Overall, our data support the potential for engineering CXCR3-A expression to enhance CAR T cell trafficking and efficacy against DIPG.
- 11 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Open AccessEngineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma
Diffuse intrinsic pontine glioma (DIPG) is a fatal brainstem tumor desperately in need of better treatments. Chimeric antigen receptor (CAR) T cell therapies for DIPG have demonstrated clinical tolerability and bioactivity, but not universal benefit. A major obstacle is insufficient CAR T cell trafficking to the tumor. As our recent clinical trials have demonstrated locoregional elevation of CXCL10, a ligand of the chemokine receptor CXCR3, here we aim to leverage this CXCL10 upregulation to enhance cell trafficking by engineering our B7-H3-targeting CAR T cells to overexpress CXCR3 variants. We demonstrate that, compared to unmodified B7-H3 CAR T cells, CXCR3-A-modified CAR T cells migrate more efficiently toward CXCR3 ligands in vitro, and when delivered intracerebroventricularly in orthotopic DIPG mouse models, CXCR3-A-modified CAR T cells show enhanced trafficking into the tumor and improved therapeutic efficacy. Overall, our data support the potential for engineering CXCR3-A expression to enhance CAR T cell trafficking and efficacy against DIPG.
- 29 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (5) , 890-902
Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors
Central nervous system (CNS) tumors are a leading cause of pediatric cancer-related death. Chimeric antigen receptor (CAR) T cells are an innovative approach for these affected children who are in desperate need of novel therapies, but CNS-directed cellular therapies have only recently advanced to the clinic. Although early-phase trials have begun to demonstrate the feasibility of manufacturing fractionated doses and the tolerability of repeated infusions for children with CNS tumors, major challenges remain. In this review, we will take an inventory of the current state of the pediatric CNS CAR T-cell field through the lens of translational obstacles to broader clinical success. Significance: CNS tumors are the leading cause of cancer-related death in children, highlighting the dire need for new treatment strategies. CAR T cells represent a unique approach, distinct from the cytotoxic chemotherapies and small-molecule inhibitors that have dominated the clinical trial space for decades. Phase I CAR T-cell trials have shown feasibility and possible efficacy against pediatric CNS tumors; however, many challenges must be overcome if these therapeutics are going to be beneficial to most affected children. Although rapid translational development and early-phase trials have quickly evolved our understanding, the pediatric CNS CAR T-cell community now yearns for critical assessments and open dialogue about overcoming the remaining obstacles ahead.
- 29 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (5) , 890-902
Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors
Central nervous system (CNS) tumors are a leading cause of pediatric cancer-related death. Chimeric antigen receptor (CAR) T cells are an innovative approach for these affected children who are in desperate need of novel therapies, but CNS-directed cellular therapies have only recently advanced to the clinic. Although early-phase trials have begun to demonstrate the feasibility of manufacturing fractionated doses and the tolerability of repeated infusions for children with CNS tumors, major challenges remain. In this review, we will take an inventory of the current state of the pediatric CNS CAR T-cell field through the lens of translational obstacles to broader clinical success. Significance: CNS tumors are the leading cause of cancer-related death in children, highlighting the dire need for new treatment strategies. CAR T cells represent a unique approach, distinct from the cytotoxic chemotherapies and small-molecule inhibitors that have dominated the clinical trial space for decades. Phase I CAR T-cell trials have shown feasibility and possible efficacy against pediatric CNS tumors; however, many challenges must be overcome if these therapeutics are going to be beneficial to most affected children. Although rapid translational development and early-phase trials have quickly evolved our understanding, the pediatric CNS CAR T-cell community now yearns for critical assessments and open dialogue about overcoming the remaining obstacles ahead.
- Open Access
- 1 April 2025
- Published by Springer Nature in Research Square
Engineered CXCR3-A expression enhances the trafficking and efficacy of intracerebroventricularly delivered B7-H3-targeting CAR T cells against diffuse intrinsic pontine glioma
Diffuse intrinsic pontine glioma (DIPG) is a fatal brainstem tumor desperately in need of better treatments. CAR T cell therapies for DIPG have demonstrated clinical tolerability and bioactivity, but not universal benefit. A major obstacle is insufficient CAR T cell trafficking to the tumor. As our clinical trials have demonstrated locoregional elevation of CXCL10, a ligand of the chemokine receptor CXCR3, we aimed to leverage this CXCL10 to enhance cell trafficking by engineering our B7-H3-targeting CAR T cells to overexpress CXCR3 variants. Here, we demonstrate that, compared to unmodified B7-H3 CAR T cells, CXCR3-A-modified CAR T cells migrate more efficiently toward CXCR3 ligands in vitro, and when delivered intracerebroventricularly in orthotopic DIPG mouse models, CXCR3-A-modified CAR T cells show enhanced trafficking into the tumor and improved therapeutic efficacy. Overall, our data support the potential for engineering CXCR3-A expression to enhance CAR T cell trafficking and efficacy against DIPG.
- 1 April 2025
- Published by Springer Nature in Research Square
Open AccessEngineered CXCR3-A expression enhances the trafficking and efficacy of intracerebroventricularly delivered B7-H3-targeting CAR T cells against diffuse intrinsic pontine glioma
Diffuse intrinsic pontine glioma (DIPG) is a fatal brainstem tumor desperately in need of better treatments. CAR T cell therapies for DIPG have demonstrated clinical tolerability and bioactivity, but not universal benefit. A major obstacle is insufficient CAR T cell trafficking to the tumor. As our clinical trials have demonstrated locoregional elevation of CXCL10, a ligand of the chemokine receptor CXCR3, we aimed to leverage this CXCL10 to enhance cell trafficking by engineering our B7-H3-targeting CAR T cells to overexpress CXCR3 variants. Here, we demonstrate that, compared to unmodified B7-H3 CAR T cells, CXCR3-A-modified CAR T cells migrate more efficiently toward CXCR3 ligands in vitro, and when delivered intracerebroventricularly in orthotopic DIPG mouse models, CXCR3-A-modified CAR T cells show enhanced trafficking into the tumor and improved therapeutic efficacy. Overall, our data support the potential for engineering CXCR3-A expression to enhance CAR T cell trafficking and efficacy against DIPG.
- Open Access
- 1 March 2022
- Published by Elsevier in Molecular Therapy
- Vol. 30 (3) , 1201-1214
Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase
- 1 March 2022
- Published by Elsevier in Molecular Therapy
- Vol. 30 (3) , 1201-1214
Open AccessEnhancing CAR T function with the engineered secretion of C. perfringens neuraminidase